Ticker Details
Celldex Therapeutics, Inc. Celldex Therapeutics Inc is a biopharmaceutical company. The company is engaged in the development and commercialization of immunotherapy technologies for the treatment of cancer and other difficult-to-treat diseases.
IPO Date:	March 26, 1990
Sector:	Healthcare
Industry:	Biotech
Market Cap:	$2.78B
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$0.49 | 3.41%
Avg Daily Range (30 D):	$0.74 | 2.18%
Avg Daily Range (90 D):	$0.72 | 2.22%

Institutional Daily Volume
Avg Daily Volume:	.86M
Avg Daily Volume (30 D):	.84M
Avg Daily Volume (90 D):	.78M

Trade Size
Avg Trade Size (Sh.):	154
Avg Trade Size (Sh.) (30 D):	67
Avg Trade Size (Sh.) (90 D):	60

Institutional Trades
Total Institutional Trades:	5,007
Avg Institutional Trade:	$2.18M
Avg Institutional Trade (30 D):	$4.12M
Avg Institutional Trade (90 D):	$3.73M
Avg Institutional Trade Volume:	.06M
Avg Institutional Trades (Per Day):	2

Market Closing Trades
Avg Closing Trade:	$3.03M
Avg Closing Trade (30 D):	$8.55M
Avg Closing Trade (90 D):	$6.4M
Avg Closing Volume:	83.96K

News

Jun 14, 2026 @ 2:21 PM Celldex Presents Long-Term Barzolvolimab Results D... Source: Na

Jun 14, 2026 @ 9:15 AM Celldex Presents Positive First-in-Human Results f... Source: Na

Apr 6, 2026 @ 2:53 PM Celldex Therapeutics Announces Closing of Public O... Source: Celldex Therapeutics, Inc.

Apr 2, 2026 @ 1:48 AM Celldex Announces Pricing of $300 Million Public O... Source: Na

Mar 1, 2026 @ 2:45 PM Celldex Presents Positive Data Demonstrating Barzo... Source: Celldex

Financials
	TTM	Q4 2025	FY 2025
Basic EPS	$-1.18	$-1.23	$-3.9
Diluted EPS	$-1.18	$-1.23	$-3.9
Revenue	$.02M	$.12M	$1.55M
Gross Profit			$1.35M
Net Income / Loss	$-78.69M	$-81.32M	$-258.76M
Operating Income / Loss	$-84.44M	$-87.15M	$-287.37M
Cost of Revenue			$.2M
Net Cash Flow	$6.86M	$-7.17M	$.52M
PE Ratio

Splits
Feb 11, 2019	1:15
Mar 10, 2008	1:12
Mar 07, 2008	1:12